1
|
Rojas JD, Reynolds ND, Pike BL, Espinoza NM, Kuroiwa J, Jani V, Ríos PA, Nunez RG, Yori PP, Bernal M, Meza RA, Kosek MN, McCoy AJ, Simons MP, Gregory MJ, Guerry P, Poly FM. Distribution of Capsular Types of Campylobacter jejuni Isolates from Symptomatic and Asymptomatic Children in Peru. Am J Trop Med Hyg 2020; 101:541-548. [PMID: 31392944 PMCID: PMC6726929 DOI: 10.4269/ajtmh.18-0994] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
Campylobacter jejuni is the leading bacterial cause of diarrhea worldwide. A capsular polysaccharide (CPS) conjugate vaccine is under development and requires determination of the valency. However, distribution of CPS types circulating globally is presently poorly described. We aimed to determine whether CPS type distribution in Peru differs from that in other endemic regions. We used a multiplex polymerase chain reaction (PCR) assay for the detection of CPS encoding genes capable of distinguishing all 35 CPS types on Campylobacter isolates in two prospective communities based studies conducted in cohorts of children less than 59 months of age in Peru. Results showed that CPS type HS4 complex was the most prevalent, followed by HS3 complex and HS15. Differences in CPS type for symptomatology were not statistically significant. Most subjects demonstrated repeated infections over time with different CPS types, suggesting that CPS types may confer of a level of homologous protective immunity. In this dataset, some differences in CPS type distribution were observed in comparison to other low-middle income countries. Further studies need to be conducted in endemic areas to increase our knowledge of CPS type distribution and guide vaccine development.
Collapse
Affiliation(s)
- Jesús D Rojas
- Bacteriology Department, Naval Medical Research Unit-6 (NAMRU-6), Lima, Peru.,Facultad de Ciencias Biológicas, Universidad Nacional Mayor de San Marcos, Lima, Peru
| | | | - Brian L Pike
- U.S. National Medical Research Center, Singapore
| | - Nereyda M Espinoza
- Bacteriology Department, Naval Medical Research Unit-6 (NAMRU-6), Lima, Peru
| | - Janelle Kuroiwa
- Enteric Diseases Department, Infectious Diseases Directorate, Naval Medical Research Center, Silver Spring, Maryland
| | - Vihasi Jani
- Enteric Diseases Department, Infectious Diseases Directorate, Naval Medical Research Center, Silver Spring, Maryland
| | - Paul A Ríos
- Bacteriology Department, Naval Medical Research Unit-6 (NAMRU-6), Lima, Peru
| | - Rosa G Nunez
- Bacteriology Department, Naval Medical Research Unit-6 (NAMRU-6), Lima, Peru
| | - Pablo P Yori
- Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, Virginia
| | - Manuela Bernal
- Bacteriology Department, Naval Medical Research Unit-6 (NAMRU-6), Lima, Peru
| | - Rina A Meza
- Bacteriology Department, Naval Medical Research Unit-6 (NAMRU-6), Lima, Peru
| | - Margaret N Kosek
- Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, Virginia
| | - Andrea J McCoy
- Bacteriology Department, Naval Medical Research Unit-6 (NAMRU-6), Lima, Peru
| | - Mark P Simons
- Bacteriology Department, Naval Medical Research Unit-6 (NAMRU-6), Lima, Peru
| | - Michael J Gregory
- Bacteriology Department, Naval Medical Research Unit-6 (NAMRU-6), Lima, Peru
| | - Patricia Guerry
- Enteric Diseases Department, Infectious Diseases Directorate, Naval Medical Research Center, Silver Spring, Maryland
| | - Frédéric M Poly
- Enteric Diseases Department, Infectious Diseases Directorate, Naval Medical Research Center, Silver Spring, Maryland
| |
Collapse
|
2
|
Stoppato M, Gaspar C, Regeimbal J, Nunez RG, Giuntini S, Schiller ZA, Gawron MA, Pondish JR, Martin JC, Schneider MI, Klempner MS, Cavacini LA, Wang Y. Oral administration of an anti-CfaE secretory IgA antibody protects against Enterotoxigenic Escherichia coli diarrheal disease in a nonhuman primate model. Vaccine 2020; 38:2333-2339. [PMID: 32008877 DOI: 10.1016/j.vaccine.2020.01.064] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2019] [Revised: 01/17/2020] [Accepted: 01/21/2020] [Indexed: 11/28/2022]
Abstract
Enterotoxigenic Escherichia coli (ETEC) is a leading cause of diarrhea-associated illness in developing countries. There is currently no vaccine licensed to prevent ETEC and the development of an efficacious prophylaxis would provide an intervention with significant impact. Recent studies suggested that effective protection could be achieved by inducing immunity to block colonization of ETEC. Here, we evaluated the efficacy of secretory (s) IgA2 and dimeric (d) IgA2 of an anti-colonization factor antigen antibody, 68-61, in the Aotus nancymaae nonhuman primate (NHP) ETEC challenge model via oral and parental delivery. Thirty-nine animals were distributed across 3 groups of 13, and challenged with 5.0x1011 colony forming unit (CFU) of H10407 on Day 0. Group 1 received a dIgA2 68-61 subcutaneously on day 0. Group 2 received a SIgA2 68-61 orally on days -1, 0, and +1, and Group 3 received an irrelevant SIgA2 antibody orally on days -1, 0, and +1. All animals were observed for symptoms of diarrhea, and stools were collected for ETEC colony counts. Anti-CfaE SIgA2 treatment significantly lowered the attack rate, resulting in a protective efficacy of 74.1% (p = 0.025) in Group 2 as compared to Group 3. The anti-CfaE dIgA2 treatment group had reduced diarrheal attack rate, although the reduction did not reach significance (57.1%; p = 0.072) as compared to the irrelevant SIgA2 Group 3. Our results demonstrated the feasibility of oral administration of SIgA as a potential immunoprophylaxis against enteric infections. To our knowledge, this is the first study to demonstrate the efficacy of administrated SIgA in a nonhuman primate model.
Collapse
Affiliation(s)
- Matteo Stoppato
- MassBiologics of the University of Massachusetts Medical School, Boston, MA, USA
| | | | - James Regeimbal
- MassBiologics of the University of Massachusetts Medical School, Boston, MA, USA
| | - Rosa G Nunez
- MassBiologics of the University of Massachusetts Medical School, Boston, MA, USA
| | - Serena Giuntini
- MassBiologics of the University of Massachusetts Medical School, Boston, MA, USA
| | - Zachary A Schiller
- MassBiologics of the University of Massachusetts Medical School, Boston, MA, USA
| | - Melissa A Gawron
- MassBiologics of the University of Massachusetts Medical School, Boston, MA, USA
| | - Jessica R Pondish
- MassBiologics of the University of Massachusetts Medical School, Boston, MA, USA
| | - Joseph C Martin
- MassBiologics of the University of Massachusetts Medical School, Boston, MA, USA
| | - Matthew I Schneider
- MassBiologics of the University of Massachusetts Medical School, Boston, MA, USA
| | - Mark S Klempner
- MassBiologics of the University of Massachusetts Medical School, Boston, MA, USA.
| | - Lisa A Cavacini
- MassBiologics of the University of Massachusetts Medical School, Boston, MA, USA.
| | - Yang Wang
- MassBiologics of the University of Massachusetts Medical School, Boston, MA, USA.
| |
Collapse
|